Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation - Takeaways - MDSpire

Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation

  • By

  • Aleksi K. Winstén

  • Ville Langén

  • K.E. Juhani Airaksinen

  • Konsta Teppo

  • June 8, 2026

  • 0 min

Share

  • 1

    Anticoagulation therapy for subclinical atrial fibrillation (AF) shows modest stroke risk reduction but increases major bleeding risk.

  • 2

    A modeling study indicated that the net benefit of direct oral anticoagulant (DOAC) therapy in subclinical AF is minimal and uncertain.

  • 3

    Cost-effectiveness of DOAC therapy was evaluated using a Markov model, focusing on quality-adjusted life-years (QALYs) and incremental costs.

  • 4

    The study utilized a health system perspective, considering direct medical costs while excluding nonmedical costs and productivity losses.

  • 5

    Patients developing clinical AF were modeled with average outcomes regardless of prior anticoagulation treatment in the analysis.

Original Source(s)

Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation

  • by Aleksi K. Winstén, Ville Langén, K.E. Juhani Airaksinen, Konsta Teppo

  • June 8, 2026

Related Content

Linking atrial fibrillation to cerebral small vessel disease: a cross-sectional study with predictive analytics

From anti-inflammation to pro-resolution: a new paradigm for specialized pro-resolving mediators in regulating neuroinflammation and repair after cerebral ischemia-reperfusion

One-year outcomes of thoracic endovascular stent graft repair for acute type B aortic penetrating ulcer combined with antiplatelet drugs